Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
José Manuel SousaMercedes VergaraFederico PulidoGloria Sánchez AntolínLander HijonaFernando CarnicerDiego RincónJavier SalmerónBeatriz Mateos-MuñozAntoni JouBenjamín Polo-LorduyÁngel RubínAna EscardaPatricia AguilarTeresa Aldámiz-EchevarríaLuisa García-BueyJose Antonio CarriónManuel Hernández-GuerraSonia Chimeno-HernándezNuria EspinosaRosa María MorillasRaúl J AndradeManuel DelgadoAdolfo GallegoMarta MagazJosé María Moreno-PlanasÁngel EstébanezMikel RicoFernando MenéndezBlanca SampedroLuis Enrique MoranoSonia IzquierdoJosé Manuel ZozayaManuel RodríguezSenador Morán-SánchezSara LorenteIgnacio Martín-GranizoMiguel Ángel Von-WichmannMarcial DelgadoAmanda ManzanaresPublished in: PloS one (2019)
Our results confirm that OBV/PTV/r ± DSV ± RBV is effective and generally well tolerated in a representative sample of the HCV monoinfected and HCV/HIV coinfected population in Spain within the experience of a national strategic plan to tackle HCV.